364 related articles for article (PubMed ID: 33546635)
1. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety.
Wang Z; Lu J; Huang W; Wu Z; Gong J; Wang Q; Liu Q; Wang C; Zhu Y; Ding X; Wang Z
BMC Cancer; 2021 Feb; 21(1):124. PubMed ID: 33546635
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous Image-Guided Thermal Ablation for Multifocal Renal Cell Carcinoma: 10-Year Experience at a Single Center.
Zhou W; Uppot RN; Feldman AS; Arellano RS
AJR Am J Roentgenol; 2017 Oct; 209(4):733-739. PubMed ID: 28678572
[TBL] [Abstract][Full Text] [Related]
3. Irreversible Electroporation for Surgical Renal Masses in Solitary Kidneys: Short-Term Interventional and Functional Outcome.
Diehl SJ; Rathmann N; Kostrzewa M; Ritter M; Smakic A; Schoenberg SO; Kriegmair MC
J Vasc Interv Radiol; 2016 Sep; 27(9):1407-1413. PubMed ID: 27292599
[TBL] [Abstract][Full Text] [Related]
4. Minimally Invasive Percutaneous Treatment of Small Renal Tumors with Irreversible Electroporation: A Single-Center Experience.
Trimmer CK; Khosla A; Morgan M; Stephenson SL; Ozayar A; Cadeddu JA
J Vasc Interv Radiol; 2015 Oct; 26(10):1465-71. PubMed ID: 26250855
[TBL] [Abstract][Full Text] [Related]
5. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
[TBL] [Abstract][Full Text] [Related]
6. R.E.N.A.L. (Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines) nephrometry score predicts early tumor recurrence and complications after percutaneous ablative therapies for renal cell carcinoma: a 5-year experience.
Camacho JC; Kokabi N; Xing M; Master VA; Pattaras JG; Mittal PK; Kim HS
J Vasc Interv Radiol; 2015 May; 26(5):686-93. PubMed ID: 25769213
[TBL] [Abstract][Full Text] [Related]
7. Intermediate outcomes and predictors of efficacy in the radiofrequency ablation of 100 pathologically proven renal cell carcinomas.
McClure TD; Chow DS; Tan N; Sayre JA; Pantuck AJ; Raman SS
J Vasc Interv Radiol; 2014 Nov; 25(11):1682-8; quiz 1689. PubMed ID: 25081202
[TBL] [Abstract][Full Text] [Related]
8. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
9. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.
Wendler JJ; Ricke J; Pech M; Fischbach F; Jürgens J; Siedentopf S; Roessner A; Porsch M; Baumunk D; Schostak M; Köllermann J; Liehr UB
Cardiovasc Intervent Radiol; 2016 Feb; 39(2):239-50. PubMed ID: 26341653
[TBL] [Abstract][Full Text] [Related]
10. Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience.
Wah TM; Lenton J; Smith J; Bassett P; Jagdev S; Ralph C; Vasudev N; Bhattarai S; Kimuli M; Cartledge J
Eur Radiol; 2021 Oct; 31(10):7491-7499. PubMed ID: 33825033
[TBL] [Abstract][Full Text] [Related]
11. Image-Guided Thermal Ablation for Non-resectable Recurrence of Renal Cell Cancer Following Nephrectomy: Clinical Experience with Eleven Patients.
Zhou W; Herwald SE; Uppot RN; Arellano RS
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1743-1750. PubMed ID: 29721615
[TBL] [Abstract][Full Text] [Related]
12. Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.
Wendler JJ; Pech M; Köllermann J; Friebe B; Siedentopf S; Blaschke S; Schindele D; Porsch M; Baumunk D; Jürgens J; Fischbach F; Ricke J; Schostak M; Böhm M; Liehr UB
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):466-476. PubMed ID: 28929209
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes.
Zhou W; Herwald SE; McCarthy C; Uppot RN; Arellano RS
J Vasc Interv Radiol; 2019 Jul; 30(7):1035-1042. PubMed ID: 30956075
[TBL] [Abstract][Full Text] [Related]
14. Image-guided ablation of renal cell carcinoma.
Wah TM
Clin Radiol; 2017 Aug; 72(8):636-644. PubMed ID: 28527529
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.
Wah TM; Irving HC; Gregory W; Cartledge J; Joyce AD; Selby PJ
BJU Int; 2014 Mar; 113(3):416-28. PubMed ID: 24053769
[TBL] [Abstract][Full Text] [Related]
16. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and safety of irreversible electroporation (IRE) in patients with small renal masses: Results of a prospective study.
Buijs M; Zondervan PJ; de Bruin DM; van Lienden KP; Bex A; van Delden OM
Urol Oncol; 2019 Mar; 37(3):183.e1-183.e8. PubMed ID: 30509869
[TBL] [Abstract][Full Text] [Related]
18. CT-Guided Radiofrequency Ablation of T1a Renal Cell Carcinoma in Korea: Mid-Term Outcomes.
Kim HJ; Park BK; Park JJ; Kim CK
Korean J Radiol; 2016; 17(5):763-70. PubMed ID: 27587966
[TBL] [Abstract][Full Text] [Related]
19. Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation.
Zhou W; Arellano RS
J Vasc Interv Radiol; 2018 Jul; 29(7):943-951. PubMed ID: 29628298
[TBL] [Abstract][Full Text] [Related]
20. Risk Assessment of Chronic Kidney Disease following Microwave Ablation for Stage T1 Renal Cell Carcinoma.
Zhou W; Herwald SE; Uppot RN; Arellano RS
J Vasc Interv Radiol; 2018 Dec; 29(12):1685-1691. PubMed ID: 30297311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
